Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 0.81 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.81 |
| ▸ | BRAF | P15056 | 3/20 | 0.81 |
| ▸ | RET | P07949 | 3/20 | 0.81 |
| ▸ | GSK3B | P49841 | 2/20 | 0.81 |
| ▸ | ARAF | P10398 | 2/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | KIT | P10721 | 2/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.81 |
| ▸ | FLT1 | P17948 | 2/20 | 0.81 |
| ▸ | MAOA | P21397 | 2/20 | 0.81 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.81 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481765 | 0.93 | RAF1 (0.86) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL13471762 | 0.92 | RAF1 (0.84) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL2480623 | 0.92 | RAF1 (0.84) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL13471761 | 0.92 | RAF1 (0.84) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL14964383 | 0.91 | RAF1 (0.84) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL3707691 | 0.91 | RAF1 (0.83) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL22001800 | 0.90 | RAF1 (0.82) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL20909069 | 0.90 | RAF1 (0.82) | RAF1KDRPDGFRBBRAFRET | |
| SCHEMBL22473654 | 0.90 | RAF1 (0.82) | RAF1KDRPDGFRBBRAFRET | |
| Sorafenib SCHEMBL15921371 | 0.90 | RAF1 (0.93) | RAF1KDRPDGFRBBRAFRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2786750-A1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | Ajinomoto Co., Inc. (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2324825-A1 | Aryl ureas with angiogenesis inhibiting activity | Bayer Healthcare LLC (US) | 2011-05-25 | — | — | EP | claimed |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-9651554-B2 | Molecular diagnostic methods for predicting brain metastasis of breast cancer | THE METHODIST HOSPITAL RESEARCH INSTITUTE (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2786750-A1 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | Ajinomoto Co., Inc. (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-8618141-B2 | Aryl ureas with angiogenesis inhibiting activity | BAYER HEALTHCARE LLC (US) | 2013-12-31 | — | — | US | disclosed |
| EP-1478358-B1 | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis | BAYER HEALTHCARE LLC (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8445687-B2 | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process | CIPLA LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | BAYER PHARMACEUTICALS CORPORATION | 2009-03-12 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | BAYER HEALTHCARE LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885KDR 1151/4885PDGFRB 1422/4885 |
| US-20180296541-A9 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20070020704-A1 | Diaryl ureas with kinase inhibiting activity | FLT4, FLT1, FLT3 | RAF1 51/4885KDR 44/4885PDGFRB 25/4885 |
| US-10653684-B2 | Aryl ureas with angiogenisis inhibiting activity | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20090068146-A1 | DIARYL UREAS AND COMBINATIONS | NR4A1, NAP1L4, NR4A3 | RAF1 4118/4885KDR 2385/4885PDGFRB 3206/4885 |
| US-20120289552-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | FLT4, FLT1, KDR | RAF1 817/4885KDR 3/4885PDGFRB 137/4885 |
| US-20160015697-A1 | ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY | FLT1, FLT4, KDR | RAF1 867/4885KDR 3/4885PDGFRB 117/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | RAF1 1304/4885KDR 1628/4885PDGFRB 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.